Search results
CEL-SCI's Lead Head & Neck Cancer Candidate Shows 43% Survival Extension
Benzinga via Yahoo Finance· 1 year agoCEL-SCI Corporation (NASDAQ: CVM) reported new data from its pivotal Phase 3 study of Multikine...
Why CEL-SCI Shares Are Shooting Higher Today
Benzinga via Yahoo Finance· 1 year agoCEL-SCI Corporation (NYSE: CVM) announced that the latest results from its pivotal Phase 3 study of Multikine, a presurgical cancer immunotherapy, were...
10-Year Phase 3 Trial Shows CEL-SCI's Multikine immunotherapy Extends Lives In Head & Neck Cancer...
Benzinga via Yahoo Finance· 2 years agoCEL-SCI Corporation (NYSE: CVM) said that its 10-year Phase 3 trial showed that Multikine...
Cel-Sci: Fiscal Q2 Earnings Snapshot
Associated Press Finance via Yahoo Finance· 3 weeks agoVIENNA, Va. (AP) — VIENNA, Va. (AP) — Cel-Sci Corp. (CVM) on Thursday reported a loss of $7.2 million in its fiscal second quarter. The Vienna, Virginia-based company said it had a loss of 14 ...
12 Best Day Trading Stocks To Buy
Insider Monkey via Yahoo Finance· 7 months agoIn this article, we discuss the 12 best day trading stocks to buy. If you want to read about some more day trading stocks, go directly to 5 Best Day...
